Bone Biologics (BBLG) Earnings Analysis

Bone Biologics (BBLG) next reports earnings on 2026-08-13, consensus EPS -0.39 USD. Last quarter (2026-05-14) it beat with EPS -0.43 USD vs -0.43 USD est (0%). It has beaten estimates in 5/8 recent quarters (63%). Trailing P/E -0.40.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does BBLG next report earnings?

Next earnings date2026-08-13
Consensus EPS estimate-0.39 USD
Revenue estimaten/a

BBLG earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-14-0.43 USD-0.43 USD0%Beat
2026-03-02-0.14 USD-0.34 USD+58.8%Beat
2025-11-14-0.37 USD-1.23 USD+69.9%Beat
2025-08-14-1.33 USD-0.58 USD-129.3%Miss
2025-05-12-1.92 USD-0.48 USD-300%Miss
2025-03-05-0.61 USD-0.65 USD+6.2%Beat
2024-11-14-14.22 USD-3.6 USD-295%Miss
2024-08-09-4.02 USD-8.34 USD+51.8%Beat

Beat rate: 5/8 (63%) over reported quarters with consensus data.

BBLG valuation and analyst view

Trailing P/E-0.40
Trailing EPS-1.59191 USD
Price / book0.42
Dividend yield0.00%
Market cap0.00B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Bone Biologics (BBLG)'s next earnings date?

Bone Biologics is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.39 USD.

Did BBLG beat earnings last quarter?

In its 2026-05-14 report, BBLG posted EPS of -0.43 USD versus a -0.43 USD estimate — a beat of 0%.

What is BBLG's earnings track record?

Over the last 8 reported quarters with consensus data, BBLG beat estimates 5 times (63%).

What is BBLG's current P/E ratio and EPS?

BBLG trades at a trailing P/E of -0.40 on trailing EPS of -1.591907021824137 USD.

What do analysts rate BBLG?

BBLG has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.